Kidney Fibrosis (Genitourinary Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis – Drugs In Development, 2021, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 36 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).

– The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AdAlta Ltd

Alentis Therapeutics AG

Algernon Pharmaceuticals Inc

Angion Biomedica Corp

AstraZeneca Plc

BiOrion Technologies BV

Blade Therapeutics Inc

Cellmid Ltd

CohBar Inc

Curacle Co Ltd

Epigen Biosciences Inc

Evotec SE

Future Medicine Co Ltd

Galapagos NV

Galectin Therapeutics Inc

GenKyoTex SA

Hepion Pharmaceuticals Inc

iBio Inc

Isarna Therapeutics GmbH

Kadmon Corp LLC

Liminal BioSciences Inc

Max Biopharma Inc

Mission Therapeutics Ltd

NB Health Laboratory Co Ltd

Novo Nordisk AS

Osteoneurogen Inc

Pharmaxis Ltd

Rubedo Life Sciences Inc

Sanofi

Scholar Rock Inc

Secarna Pharmaceuticals GmbH & Co KG

Senolytic Therapeutics Inc

TRACON Pharmaceuticals Inc

Transcenta Holding Ltd

UCB SA

Vascular Biogenics Ltd

Vectus Biosystems Ltd

Table of Contents

Table of Contents

Introduction

Kidney Fibrosis - Overview

Kidney Fibrosis - Therapeutics Development

Kidney Fibrosis - Therapeutics Assessment

Kidney Fibrosis - Companies Involved in Therapeutics Development

Kidney Fibrosis - Drug Profiles

Kidney Fibrosis - Dormant Projects

Kidney Fibrosis - Discontinued Products

Kidney Fibrosis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Kidney Fibrosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Target, 2021 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Kidney Fibrosis – Pipeline by AdAlta Ltd, 2021

Kidney Fibrosis – Pipeline by Alentis Therapeutics AG, 2021

Kidney Fibrosis – Pipeline by Algernon Pharmaceuticals Inc, 2021

Kidney Fibrosis – Pipeline by Angion Biomedica Corp, 2021

Kidney Fibrosis – Pipeline by AstraZeneca Plc, 2021

Kidney Fibrosis – Pipeline by BiOrion Technologies BV, 2021

Kidney Fibrosis – Pipeline by Blade Therapeutics Inc, 2021

Kidney Fibrosis – Pipeline by Cellmid Ltd, 2021

Kidney Fibrosis – Pipeline by CohBar Inc, 2021

Kidney Fibrosis – Pipeline by Curacle Co Ltd, 2021

Kidney Fibrosis – Pipeline by Epigen Biosciences Inc, 2021

Kidney Fibrosis – Pipeline by Evotec SE, 2021

Kidney Fibrosis – Pipeline by Future Medicine Co Ltd, 2021

Kidney Fibrosis – Pipeline by Galapagos NV, 2021

Kidney Fibrosis – Pipeline by Galectin Therapeutics Inc, 2021

Kidney Fibrosis – Pipeline by GenKyoTex SA, 2021

Kidney Fibrosis – Pipeline by Hepion Pharmaceuticals Inc, 2021

Kidney Fibrosis – Pipeline by iBio Inc, 2021

Kidney Fibrosis – Pipeline by Isarna Therapeutics GmbH, 2021

Kidney Fibrosis – Pipeline by Kadmon Corp LLC, 2021

Kidney Fibrosis – Pipeline by Liminal BioSciences Inc, 2021

Kidney Fibrosis – Pipeline by Max Biopharma Inc, 2021

Kidney Fibrosis – Pipeline by Mission Therapeutics Ltd, 2021

Kidney Fibrosis – Pipeline by NB Health Laboratory Co Ltd, 2021

Kidney Fibrosis – Pipeline by Novo Nordisk AS, 2021

Kidney Fibrosis – Pipeline by Osteoneurogen Inc, 2021

Kidney Fibrosis – Pipeline by Pharmaxis Ltd, 2021

Kidney Fibrosis – Pipeline by Rubedo Life Sciences Inc, 2021

Kidney Fibrosis – Pipeline by Sanofi, 2021

Kidney Fibrosis – Pipeline by Scholar Rock Inc, 2021

Kidney Fibrosis – Pipeline by Secarna Pharmaceuticals GmbH & Co KG, 2021

Kidney Fibrosis – Pipeline by Senolytic Therapeutics Inc, 2021

Kidney Fibrosis – Pipeline by TRACON Pharmaceuticals Inc, 2021

Kidney Fibrosis – Pipeline by Transcenta Holding Ltd, 2021

Kidney Fibrosis – Pipeline by UCB SA, 2021

Kidney Fibrosis – Pipeline by Vascular Biogenics Ltd, 2021

Kidney Fibrosis – Pipeline by Vectus Biosystems Ltd, 2021

Kidney Fibrosis – Dormant Projects, 2021

Kidney Fibrosis – Dormant Projects, 2021 (Contd..1)

Kidney Fibrosis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Kidney Fibrosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports